Sara E Berman

Dr. Sara E Berman


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2022 in Magnetic Resonance Imaging
Verified
Journal Article
Closed access
GRGrant S. Roberts
Grant S. Roberts
CHCarson A. Hoffman
Carson A. Hoffman
LRLeonardo A. Rivera-Rivera
Leonardo A. Rivera-Rivera
SBSara E Berman
Sara E Berman
LELaura B. Eisenmenger
Laura B. Eisenmenger
OWOliver Wieben
Oliver Wieben

18 August 2025 in Cells
Verified
Journal Article
Open access
PDF file
SBSara E Berman
Sara E Berman
ASAndrew D. Siderowf
Andrew D. Siderowf
Synucleinopathies are neurodegenerative disorders defined by the pathological aggregation of α-synuclein. Several α-synuclein biomarkers have been developed to aid diagnosis and research, such as cerebrospinal fluid (CSF) and blood-based measurements, seed amplification assays (SAAs), and immunohistochemical detection from skin biopsies. While these existing biomarkers have important uses, they face limitations in diagnostic specificity, spatial localization, and the ability to monitor disease progression or response to therapy. The development of α-synuclein PET tracers, which would allow for the direct in vivo imaging of α-synuclein, represents an important unmet need in both research and the clinical care of patients with movement disorders. This review outlines the current landscape of α-synuclein biomarkers and discusses both the scientific and technical challenges in developing α-synuclein PET imaging tracers.